Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Goldsmith

Showing results (91-100 of 102) with videos related to

Pageof 11
Sort By:
Nature Medicine|August 20, 2021
Effects of a large-scale social media advertising campaign on holiday travel and COVID-19 infections: a cluster randomized controlled trialEmily Breza, Fatima Cody Stanford, Marcella Alsan, et al.
Arxiv|June 23, 2021
Doctors and Nurses Social Media Ads Reduced Holiday Travel and COVID-19 infections: A cluster randomized controlled trial in 13 StatesEmily Breza, Fatima Cody Stanford, Marcela Alsan, et al.
Journal of Medicinal Chemistry|October 12, 2011
Rational design of phosphoinositide 3-kinase α inhibitors that exhibit selectivity over the phosphoinositide 3-kinase β isoformTimothy P Heffron, Binqing Wei, Alan Olivero, et al.
Medrxiv : the Preprint Server for Health Sciences|July 7, 2021
Doctors' and Nurses' Social Media Ads Reduced Holiday Travel and COVID-19 infections: A cluster randomized controlled trial in 13 StatesEmily Breza, Fatima Cody Stanford, Marcela Alsan, et al.
Journal of the American Heart Association|February 7, 2024
Personalized Antihypertensive Treatment Optimization With Smartphone-Enabled Remote Precision Dosing of Amlodipine During the COVID-19 Pandemic (PERSONAL-CovidBP Trial)David J Collier, Mike Taylor, Thomas Godec, et al.
Journal of Medicinal Chemistry|February 17, 2022
Synthesis and Preclinical Characterization of LY3154885, a Human Dopamine D1 Receptor Positive Allosteric Modulator with an Improved Nonclinical Drug-Drug Interaction Risk ProfileJunliang Hao, James Beck, Xin Zhou, et al.
Alzheimer'S & Dementia (New York, N. Y.)|January 3, 2025
Discovery and clinical translation of ceperognastat, an O-GlcNAcase (OGA) inhibitor, for the treatment of Alzheimer's diseaseWilliam Kielbasa, Paul Goldsmith, Kevin B Donnelly, et al.
Bioorganic & Medicinal Chemistry Letters|January 26, 2010
Potent oxadiazole CGRP receptor antagonists for the potential treatment of migrainePaula L Nichols, Jonathan Brand, Michael Briggs, et al.
Clinical Pharmacology and Therapeutics|October 16, 2021
Roadmap to 2030 for Drug Evaluation in Older AdultsQi Liu, Janice B Schwartz, Patricia W Slattum, et al.
Science (New York, N.Y.)|March 10, 2022
End COVID-19 in low- and middle-income countriesAhmed Mushfiq Mobarak, Edward Miguel, Jason Abaluck, et al.
Pageof 11

Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
Nature Medicine|August 20, 2021
Effects of a large-scale social media advertising campaign on holiday travel and COVID-19 infections: a cluster randomized controlled trialEmily Breza, Fatima Cody Stanford, Marcella Alsan, et al.
Arxiv|June 23, 2021
Doctors and Nurses Social Media Ads Reduced Holiday Travel and COVID-19 infections: A cluster randomized controlled trial in 13 StatesEmily Breza, Fatima Cody Stanford, Marcela Alsan, et al.
Journal of Medicinal Chemistry|October 12, 2011
Rational design of phosphoinositide 3-kinase α inhibitors that exhibit selectivity over the phosphoinositide 3-kinase β isoformTimothy P Heffron, Binqing Wei, Alan Olivero, et al.
Medrxiv : the Preprint Server for Health Sciences|July 7, 2021
Doctors' and Nurses' Social Media Ads Reduced Holiday Travel and COVID-19 infections: A cluster randomized controlled trial in 13 StatesEmily Breza, Fatima Cody Stanford, Marcela Alsan, et al.
Journal of the American Heart Association|February 7, 2024
Personalized Antihypertensive Treatment Optimization With Smartphone-Enabled Remote Precision Dosing of Amlodipine During the COVID-19 Pandemic (PERSONAL-CovidBP Trial)David J Collier, Mike Taylor, Thomas Godec, et al.
Journal of Medicinal Chemistry|February 17, 2022
Synthesis and Preclinical Characterization of LY3154885, a Human Dopamine D1 Receptor Positive Allosteric Modulator with an Improved Nonclinical Drug-Drug Interaction Risk ProfileJunliang Hao, James Beck, Xin Zhou, et al.
Alzheimer'S & Dementia (New York, N. Y.)|January 3, 2025
Discovery and clinical translation of ceperognastat, an O-GlcNAcase (OGA) inhibitor, for the treatment of Alzheimer's diseaseWilliam Kielbasa, Paul Goldsmith, Kevin B Donnelly, et al.
Bioorganic & Medicinal Chemistry Letters|January 26, 2010
Potent oxadiazole CGRP receptor antagonists for the potential treatment of migrainePaula L Nichols, Jonathan Brand, Michael Briggs, et al.
Clinical Pharmacology and Therapeutics|October 16, 2021
Roadmap to 2030 for Drug Evaluation in Older AdultsQi Liu, Janice B Schwartz, Patricia W Slattum, et al.
Science (New York, N.Y.)|March 10, 2022
End COVID-19 in low- and middle-income countriesAhmed Mushfiq Mobarak, Edward Miguel, Jason Abaluck, et al.
Pageof 11